According to EU-Startups, Helsinki-based Gosta Labs has raised €7.5 million in Seed funding led by Voima Ventures to scale its AI operating system for oncology teams. The round included participation from COR Group, the Aho family, Reaktor, and angel investors, bringing the company’s total funding to nearly €10 million following a €1.7 million pre-Seed round earlier in 2024. Founded in 2023 by Lauri Sippola and Henri Viertolahti, who previously founded and sold Kaiku Health to Elekta, the company aims to reduce the hours clinicians spend daily on administrative work. Real-world results presented at ESMO 2025 Congress show their system cuts documentation time from several minutes to under two minutes per follow-up visit, reducing burden by over two-thirds. The timing is critical with cancer cases projected to surge to 35 million annually by 2050 across more than 100 cancer types.
European oncology AI heats up
Gosta Labs isn’t operating in a vacuum – they’re part of a broader European HealthTech funding wave in oncology AI. Swiss-based CGC Genomics raised €1.7 million for cancer genome interpretation, London’s Perci Health got €4 million for virtual cancer clinics, Barcelona’s Sycai Medical secured €3 million for early detection, and Leiden’s BIMINI Biotech landed €3 million for blood cancer treatments. That’s roughly €11.7 million in comparable 2025 oncology-AI funding announcements across the continent. But here’s the thing: Gosta’s €7.5 million represents one of the larger early-stage rounds in this segment. And their Finland headquarters stands out since none of the other notable 2025 fundings came from Nordic countries. Basically, we’re seeing real money flowing into practical AI solutions for cancer care rather than just research tools.
Why this matters beyond the hype
Look, there’s plenty of AI hype in healthcare, but Gosta seems to be delivering measurable results that actually change clinical workflows. When oncologists can complete documentation in under two minutes instead of dealing with “several hours a day” of administrative work, that’s transformative. The system automatically generates structured consultation notes, classifies Performance Status and CTCAE toxicity grades, and links decisions to international guidelines. Think about that for a second – we’re talking about technology that’s already being used in cancer centers in Finland, Switzerland, the Baltics, and Australia. It’s not some theoretical solution waiting for regulatory approval. Medical Director Dr. Razvan Popescu from Tumor Center Aargau confirmed the system has “already cut documentation time by over two-thirds for each patient visit.” That’s the kind of efficiency gain that could actually help address the coming tsunami of cancer cases.
The broader implications
What’s interesting here is how Gosta positions itself as an “AI operating system” rather than just another point solution. They’re building infrastructure for complex medical specialties, starting with oncology but potentially expandable to other areas. The team combines AI scientists with experienced oncology leaders like Chief Medical Officer Dr. Lionel Hadjadjeba, which gives them credibility where it matters most – in clinical settings. And let’s be honest: when your previous startup got acquired by a major player like Elekta, investors pay attention. Jussi Sainiemi from Voima Ventures specifically noted that Gosta’s team “has done it before and knows what good looks like.” In a sector where regulatory hurdles and clinical validation can sink even the best technology, that execution experience matters. As cancer care becomes increasingly complex with personalized treatments and fragmented data systems, solutions like Gosta’s AI platform could become essential infrastructure rather than nice-to-have tools. The race to build the foundational technology for tomorrow’s oncology clinics is officially on.
